Endocrine & Metabolic Disorders

Endocrine & Metabolic Disorders

Introduction to Endocrine & Metabolic Nursing

The endocrine system regulates vital metabolic processes, fluid balance, growth, and energy levels through the release of hormones. Systemic dysfunction of these glands leads to metabolic imbalances that require precise clinical assessment, pharmacological management, and patient education. In the DHA nursing assessment, endocrine care questions center on the pathophysiology and management of Diabetes Mellitus, the critical differences between DKA and HHS, the timing and safety of insulin administration, and the care of patients with thyroid disorders.

---

Diabetes Mellitus (DM): Type 1 vs. Type 2

Diabetes Mellitus is a metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both.

• Type 1 Diabetes Mellitus (T1DM): An autoimmune condition characterized by the destruction of pancreatic beta cells, leading to an absolute deficiency of insulin. It typically develops in children or young adults. These patients are dependent on lifelong exogenous insulin therapy to survive and are highly prone to developing diabetic ketoacidosis.
• Type 2 Diabetes Mellitus (T2DM): A progressive disorder characterized by insulin resistance (cells do not respond effectively to insulin) combined with a relative insulin secretory defect. It is strongly associated with obesity, physical inactivity, and genetic predisposition. It can be managed with lifestyle changes, oral antidiabetic agents (e.g., metformin), and sometimes insulin.

Diagnostic Criteria for Diabetes Mellitus

1. Fasting Plasma Glucose (FPG) >= 126 mg/dL (7.0 mmol/L) (no caloric intake for at least 8 hours).
2. Hemoglobin A1c (HbA1c) >= 6.5%.
3. Two-hour plasma glucose >= 200 mg/dL (11.1 mmol/L) during an Oral Glucose Tolerance Test (OGTT).
4. Random plasma glucose >= 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycemia (polyuria, polydipsia, unexplained weight loss).

---

Acute Diabetic Complications

Hypoglycemia

Hypoglycemia is defined as a blood glucose level less than 70 mg/dL (3.9 mmol/L). It occurs due to too much insulin or oral hypoglycemic agents, inadequate food intake, or excessive exercise.

• Clinical Manifestations:
  • Adrenergic (sympathetic activation): Shakiness, tremors, sweating, tachycardia, palpitations, anxiety, and hunger.
  • Neuroglycopenic (brain glucose deprivation): Headache, confusion, irritability, slurred speech, visual disturbances, lethargy, seizures, and coma.
• Nursing Intervention (The Rule of 15):
  1. Administer 15 grams of fast-acting simple carbohydrates (e.g., 4 ounces of orange juice or regular soda, 3 to 4 glucose tablets, or 1 tablespoon of honey). Do not give complex carbs or fats (like chocolate or milk) initially, as fat delays glucose absorption.
  2. Recheck blood glucose in 15 minutes.
  3. If blood glucose remains < 70 mg/dL, repeat the administration of 15 grams of simple carbohydrates and recheck in 15 minutes.
  4. Once glucose is normalized, provide a snack containing complex carbohydrates and protein (e.g., crackers with cheese, or a slice of bread) to maintain glycemic stability, unless a meal is scheduled within the hour.
• Alternative Route (Unconscious/Unable to Swallow): Administer 20 to 50 mL of 50% Dextrose (D50) intravenously over several minutes, or inject 1 mg of glucagon subcutaneously or intramuscularly.

Diabetic Ketoacidosis (DKA) vs. Hyperosmolar Hyperglycemic State (HHS)

Management of DKA and HHS

1. Fluid Resuscitation: The primary priority. Administer intravenous 0.9% Normal Saline (NS) rapidly to restore intravascular volume and renal perfusion. When blood glucose drops to approximately 250 mg/dL, switch the IV fluid to a dextrose-containing solution (e.g., 5% dextrose in 0.45% saline) to prevent hypoglycemia and rapid shifts in osmolality that can cause cerebral edema.
2. Insulin Infusion: Administer a continuous intravenous regular insulin infusion. regular insulin is the only insulin formulation that can be administered intravenously. Important clinical safety rule: Do not initiate insulin therapy if the serum potassium is < 3.3 mEq/L. Correct the hypokalemia first, as insulin shifts potassium into the cells and will worsen hypokalemia, potentially causing fatal arrhythmias.
3. Electrolyte Monitoring: Monitor potassium levels hourly. As acidosis resolves and insulin is administered, potassium levels will drop. Administer potassium replacement as prescribed once urine output is established (typically > 30 mL/hour).

---

Insulin Management

Nurses must understand the onset, peak, and duration of various insulin types. Hypoglycemia is most likely to occur at the peak of insulin action.

• Rapid-acting (e.g., Lispro, Aspart, Glulisine): Onset 15 mins, peak 1–2 hours, duration 3–5 hours. Ensure the patient's meal tray is in front of them before administering.
• Short-acting (e.g., Regular insulin): Onset 30–60 mins, peak 2–4 hours, duration 5–8 hours. Administer 30 minutes before meals. The only insulin given IV.
• Intermediate-acting (e.g., NPH): Onset 1.5–4 hours, peak 4–12 hours, duration 12–18 hours. Cloudy suspension; must be gently rolled, not shaken, before drawing up. Can be mixed with Regular insulin (draw clear Regular before cloudy NPH).
• Long-acting (e.g., Glargine, Detemir): Onset 1–2 hours, peakless (flat profile), duration 24 hours. Cannot be mixed in the same syringe with any other insulin.

---

Thyroid Disorders

Hyperthyroidism (Thyrotoxicosis)

Hyperthyroidism is characterized by excessive synthesis and secretion of thyroid hormones (T3 and T4), most commonly caused by Graves' Disease (an autoimmune disorder).

• Clinical Manifestations: Heat intolerance, unexplained weight loss with increased appetite, tachycardia, palpitations, diarrhea, anxiety, tremors, goiter (enlarged thyroid), and exophthalmos (bulging eyes).
• Thyroid Storm: A life-threatening hypermetabolic state triggered by stressors (infection, trauma, surgery) in an untreated hyperthyroid patient.
  • Symptoms: Hyperthermia (fever up to 41 °C), extreme tachycardia, agitation, delirium, seizures, and heart failure.
  • Nursing interventions: Maintain airway and oxygenation. Administer antithyroid medications (propylthiouracil or methimazole) and iodine preparations to block thyroid hormone release. Administer beta-blockers (e.g., propranolol) to control cardiovascular symptoms. Implement aggressive cooling measures (cooling blankets, acetaminophen; avoid aspirin, as it displaces thyroid hormone from binding proteins, increasing free hormone levels).

Hypothyroidism

Hypothyroidism is a deficiency of thyroid hormone production, most commonly caused by Hashimoto's Thyroiditis (autoimmune destruction of the thyroid gland) or iodine deficiency.

• Clinical Manifestations: Cold intolerance, weight gain with decreased appetite, bradycardia, lethargy, fatigue, constipation, dry skin, muscle weakness, and myxedema (non-pitting mucinous edema, particularly facial puffiness).
• Myxedema Coma: A life-threatening complication of severe, untreated hypothyroidism.
  • Symptoms: Profound hypothermia, bradycardia, hypoventilation, hypotension, hypoglycemia, and lactic acidosis.
  • Nursing interventions: Support the airway and mechanical ventilation. Administer intravenous levothyroxine (T4) and hydrocortisone as prescribed. Re-warm the patient slowly using warm blankets (avoid active re-warming to prevent peripheral vasodilation and circulatory collapse).
• Levothyroxine Patient Education:
  • Take the medication in the morning on an empty stomach, 30 to 60 minutes before breakfast, with a full glass of water.
  • Avoid taking levothyroxine concurrently with calcium, iron, or antacids (which decrease its absorption).
  • Emphasize that thyroid replacement therapy is lifelong and must not be discontinued abruptly.
  • Educate the patient to monitor and report signs of toxicity/hyperthyroidism (e.g., chest pain, rapid heart rate, nervousness, insomnia, excessive sweating).